ArticleOncoTargets and therapy2013
Update of research on the role of EZH2 in cancer progression.
Article in OncoTargets and therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.Scientific reports · 2017Pooled it
- Prediction of hub genes and key pathways associated with the radiation response of human hematopoietic stem/progenitor cells using integrated bioinformatics methods.Scientific reports · 2023Article
- Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets.MedComm · 2023Review
- EZH2 targeting to improve the sensitivity of acquired radio-resistance bladder cancer cells.Translational oncology · 2022Article
- Upregulated hsa_circ_0000129 expression promotes proliferation and migration of breast cancer cells.Oncology letters · 2021Article
- Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.Molecular cancer therapeutics · 2020Article
- [Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2020Article
- Association of clinicopathologic characteristics and outcomes withOncoTargets and therapy · 2018Article
- Bioinformatics analysis of RNA sequencing data reveals multiple key genes in uterine corpus endometrial carcinoma.Oncology letters · 2018Article
- Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition.Oncotarget · 2016Article
- EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2016Article
- [Effect of a novel EZH2 inhibitor GSK126 on prostate cancer cells].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2016Article
- Role of bacterial infection in the epigenetic regulation of Wnt antagonist WIF1 by PRC2 protein EZH2.Oncogene · 2015Article
- DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis.Acta pharmaceutica Sinica. B · 2015Article
- Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.Journal of cancer research and clinical oncology · 2015Article
- Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.Oncotarget · 2015Article
- Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM.Journal of neuro-oncology · 2015Article
- EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.Cancer biology & therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence shows that enhancer of zeste homolog 2 (E2H2) is upregulated in a broad range of cancer types, such as breast cancer, prostate cancer, ovarian cancer, and colon cancer. Therefore, inhibiting EZH2 expression may be a promising strategy for anticancer therapy. This review focuses on the current understanding of the mechanisms underlying EZH2 regulation that are involved in cancer progression. Also, it introduces two EZH2 inhibitors that target EZH2 and could be potentially applied in the treatment of cancer in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.